Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (like leukemia, lymphoma, or multiple myeloma) OR you've had a stem cell transplant for one of these cancers.
- You recently had chemotherapy (within 6 months) or take immune-suppressing medications.
- You tested positive for parainfluenza, RSV, or human metapneumovirus and have symptoms like runny nose, sore throat, or cough that started less than 7 days ago.
- Your oxygen level is 93% or higher on room air, and your chest X-ray shows only mild or no lung changes.
- You are an adult (18 or older) and agree to use effective birth control if needed.
- You do not have chronic lung diseases (like asthma or COPD), active lung infections, or other viruses (like flu or COVID-19) in the past week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
This trial tests how well the RSV vaccine works in people who have had a stem cell transplant or CAR-T therapy for blood cancer. It will help understand if the vaccine protects you against RSV, a common respiratory virus.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
This trial tests if antiviral medications can help adults with early respiratory syncytial virus (RSV) feel better faster. It is for people aged 18 to 64 who have had RSV symptoms for 4 days or less and have tested positive for the virus.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.